Inhibition of cardiac fibrosis in myocardial infarction
The described invention provides a method for treating myocardial infarction (MI) in a subject comprising administering to the subject a therapeutic amount of a pharmaceutical composition comprising a polypeptide of amino sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof made from a fusion between a first polypeptide that is a cell permeable protein (CPP) selected from the group consisting of a polypeptide of amino acid sequence YARAAARQARA (SEQ ID NO: 2), WLRRIKAWLRRIKA (SEQ ID NO: 21), WLRRIKA (SEQ ID NO: 22), YGRKKRRQRRR (SEQ ID NO: 23), FAKLAARLYR (SEQ ID NO: 25), and KAFAKLAARLYR (SEQ ID NO: 26), and a second polypeptide that is a therapeutic domain (TD), and a pharmaceutically acceptable carrier. The described invention also provides a kit comprising a composition comprising at least one MK2 inhibitor peptide; a means for administering the composition; and a packaging material.
1. A method for treating ischemia-mediated apoptosis in a peri-infarct border zone in a subject that has suffered a myocardial infarction (MI), the method comprising administering to the subject in need of such treatment a therapeutic amount of a pharmaceutical composition comprising a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof selected from the group consisting of a polypeptide of amino acid sequence FAKLAARLYRKALARQLGVAA (SEQ ID NO: 4), KAFAKLAARLYRKALARQLGVAA (SEQ ID NO: 5), YARAAARQARAKALARQLAVA (SEQ ID NO: 6), YARAAARQARAKALARQLGVA (SEQ ID NO: 7) and HRRIKAWLKKIKALARQLGVAA (SEQ ID NO: 8); and a pharmaceutically acceptable carrier,
wherein
the MI is characterized by aberrant deposition of an extracellular matrix protein, an aberrant promotion of fibroblast proliferation in the heart, an aberrant induction of myofibroblast differentiation, an aberrant promotion of attachment of myofibroblasts to an extracellular matrix or a combination thereof;
wherein when tested in vitro under hypoxic conditions, the pharmaceutical composition is effective to inhibit apoptotic cell death of ventricular cardiomyocyte cells when measured at 16 and 24 hours and atrial cardiomyocyte cells when measured at 12 hours, compared to control cells harvested at initiation of hypoxia challenge;
and
the therapeutic amount of the pharmaceutical composition is effective to inhibit apoptotic cell death of cardiomyocytes in the peri-infarct zone, wherein without the therapeutic effect, ventricular remodeling can progress to heart failure.
2. The method according to claim 1 , wherein the therapeutic amount is effective to enhance cell death of cardiac fibroblasts.
3. The method according to claim 1 , wherein the therapeutic amount is effective to inhibit caspase activity.
4. The method according to claim 3 , wherein the caspase activity is caspase 3/7 activity.
5. The method according to claim 1 , wherein the therapeutic amount is effective to enhance lactate dehydrogenase (LDH) release.
6. The method according to claim 1 , wherein the therapeutic amount is effective to inhibit heterogeneous nuclear ribonucleoprotein A0 (HNRNPA0) protein expression.
7. A method for improving cardiac function by treating ischemia-mediated apoptosis in a peri-infarct border zone after a myocardial infarction (MI) in a subject in need thereof, the method comprising administering to the subject in need thereof a therapeutic amount of a pharmaceutical composition comprising a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof selected from the group consisting of a polypeptide of amino acid sequence FAKLAARLYRKALARQLGVAA (SEQ ID NO: 4), KAFAKLAARLYRKALARQLGVAA (SEQ ID NO: 5), YARAAARQARAKALARQLAVA (SEQ ID NO: 6), YARAAARQARAKALARQLGVA (SEQ ID NO: 7) and HRRIKAWLKKIKALARQLGVAA (SEQ ID NO: 8); and a pharmaceutically acceptable carrier,
wherein
the therapeutic amount of the pharmaceutical composition is effective to inhibit apoptotic cell death of cardiomyocytes in the peri-infarct zone,
wherein when tested in vitro under hypoxic conditions, the pharmaceutical composition is effective to inhibit apoptotic cell death of ventricular cardiomyocyte cells when measured at 16 and 24 hours and atrial cardiomyocyte cells when measured at 12 hours, compared to control cells harvested at initiation of hypoxia challenge; and
wherein without the therapeutic effect, ventricular remodeling can progress to heart failure.
8. The method according to claim 7 , wherein the therapeutic amount is effective to enhance cell death of cardiac fibroblasts.
9. The method according to claim 7 , wherein the therapeutic amount is effective to inhibit caspase activity.
10. The method according to claim 9 , wherein the caspase activity is caspase 3/7 activity.
11. The method according to claim 7 , wherein the therapeutic amount is effective to enhance lactate dehydrogenase (LDH) release.
12. The method according to claim 7 , wherein the therapeutic amount is effective to inhibit heterogeneous nuclear ribonucleoprotein A0 (HNRNPA0) expression.
13. The method according to claim 1 , wherein the therapeutic amount of the pharmaceutical composition is effective
(i) to inhibit Mitogen Activated Protein Kinase Activated Protein Kinase II (MK2); and
(ii) to reduce cardiac fibrosis at a site of ischemic insult; or
(iii) to preserve cardiac muscle; or
(iv) to preserve systolic function; or
(v) to protect cardiomyocytes from an ischemic insult; or
(vi) a combination thereof.
14. The method according to claim 7 , wherein the therapeutic amount of the pharmaceutical composition is effective
(i) to inhibit Mitogen Activated Protein Kinase Activated Protein Kinase II (MK2); and
(ii) to reduce cardiac fibrosis at a site of ischemic insult; or
(iii) to preserve cardiac muscle; or
(iv) to preserve systolic function; or
(v) to protect cardiomyocytes from an ischemic insult; or
(vi) a combination thereof.